ICM Begins Dosing for Osteoarthritis Treatment in Australian Phase 1/2a Clinical Trial

[Asia Economy Reporter Lee Gwanju] Gene therapy developer ICM announced on the 31st that it has started dosing patients in the Phase 1/2a clinical trial of the osteoarthritis treatment 'ICM-203' currently underway in Australia.

ICM-203 is ICM's lead pipeline product, a gene therapy that carries therapeutic genes using AAV (adeno-associated virus). It is a product that treats osteoarthritis by injecting into the knee joint cavity to promote cartilage regeneration and suppress synovial inflammation, and has demonstrated efficacy as a disease-modifying osteoarthritis drug (DMOAD) in preclinical stages.

The first administration of ICM-203 was conducted at the Royal Adelaide Hospital in Australia on patients with moderate osteoarthritis. This clinical trial in Australia will be conducted sequentially from low to high doses in three cohorts with different dosages involving 24 patients.

Through this clinical trial, ICM plans to evaluate the safety of ICM-203 and secure efficacy data through one year of follow-up after dosing. They expect to complete dosing for all cohorts within this year and finish clinical monitoring next year.

ICM is a new drug development bio-venture company led by Professor Kim Daewon of Yonsei University’s Department of Biochemistry, developing treatments for degenerative intractable diseases using gene therapy technology based on AAV.

This content was produced with the assistance of AI translation services.